Agenus Announces Three-Year Survival Data from Phase 1b BOT+BAL Study in MSS Metastatic Colorectal Cancer to be Presented at ESMO GI 2026

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/8/2026

1. IONQ
2. IONS
3. AZN
4. SPY
5. ROIV
6. AAPL
7. NVDA
8. ACN
9. ODFL
10. USO

Go back to Agenus Announces Three-Year Survival Data from Phase 1b BOT+BAL Study in MSS Metastatic Colorectal Cancer to be Presented at ESMO GI 2026
AGENUS (NASDAQ: AGEN) Delayed: 7.79 -0.45 (5.46%)
Previous Close $8.24    52 Week High $7.49 
Open $8.14    52 Week Low $2.61 
Day High $8.18    P/E N/A 
Day Low $7.73    EPS $-1.10 
Volume 273,568